Towards population-specific pharmacogenomics in the era of next-generation sequencing

Xiangjun Ji; Baitang Ning; Jinghua Liu; Ruth Roberts; Larry Lesko; Weida Tong; Zhichao Liu; Tieliu Shi

doi:10.1016/j.drudis.2021.04.015

Towards population-specific pharmacogenomics in the era of next-generation sequencing

Drug Discov Today. 2021 Aug;26(8):1776-1783. doi: 10.1016/j.drudis.2021.04.015. Epub 2021 Apr 20.

Authors

Xiangjun Ji¹, Baitang Ning², Jinghua Liu³, Ruth Roberts⁴, Larry Lesko⁵, Weida Tong⁶, Zhichao Liu⁷, Tieliu Shi⁸

Affiliations

¹ The Center for Bioinformatics and Computational Biology, The Institute of Biomedical Sciences and School of Life Sciences, School of Statistics, East China Normal University, Shanghai 200241, China; Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
² Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., Jefferson, AR 72079, USA.
³ Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
⁴ ApconiX, BioHub at Alderley Park, Alderley Edge SK10 4TG, UK; University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
⁵ Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., Jefferson, AR 72079, USA; Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida at Lake Nona, Orlando, FL, USA.
⁶ Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., Jefferson, AR 72079, USA. Electronic address: weida.tong@fda.hhs.gov.
⁷ Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., Jefferson, AR 72079, USA. Electronic address: zhichao.liu@fda.hhs.gov.
⁸ The Center for Bioinformatics and Computational Biology, The Institute of Biomedical Sciences and School of Life Sciences, School of Statistics, East China Normal University, Shanghai 200241, China; Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., Jefferson, AR 72079, USA; National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi 530021, China. Electronic address: tlshi@bio.ecnu.edu.cn.

PMID: 33892143
DOI: 10.1016/j.drudis.2021.04.015

Abstract

Pharmacogenomics (PGx) has essential roles in identifying optimal drug responders, optimizing dosage regimens and avoiding adverse events. Population-specific therapeutic interventions that tackle the genetic root causes of clinical outcomes are an important precision medicine strategy. In this perspective, we discuss next-generation sequencing genotyping and its significance for population-specific PGx applications. We emphasize the potential of NGS for preemptive pharmacogenotyping, which is crucial to population-specific clinical studies and patient care. We also provide examples that use publicly available population-based genomics data for population-specific PGx studies. Last, we discuss the remaining challenges and regulatory efforts towards improvements in this field.

Keywords: Biomarkers; Next-generation sequencing; Pharmacogenomics; Population group.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Drug Administration Schedule
High-Throughput Nucleotide Sequencing / methods*
Humans
Pharmaceutical Preparations / administration & dosage
Pharmacogenetics / methods*
Precision Medicine / methods*

Substances

Pharmaceutical Preparations